

Johnson & Johnson and Subsidiaries**Supplementary Sales Data**

	(Unaudited; Dollars in Millions)				
	THIRD QUARTER				
	2009	2008	Total	Percent Change	
Operations				Currency	
Sales to customers by segment of business					
Consumer					
U.S.	\$ 1,691	1,769	(4.4) %	(4.4)	-
International	2,298	2,330	(1.4)	5.2	(6.6)
	3,989	4,099	(2.7)	1.1	(3.8)
Pharmaceutical					
U.S.	2,857	3,538	(19.2)	(19.2)	-
International	2,392	2,575	(7.1)	(1.9)	(5.2)
	5,249	6,113	(14.1)	(11.9)	(2.2)
Med Devices & Diagnostics					
U.S.	2,766	2,648	4.5	4.5	-
International	3,077	3,061	0.5	3.8	(3.3)
	5,843	5,709	2.3	4.1	(1.8)
U.S.	7,314	7,955	(8.1)	(8.1)	-
International	7,767	7,966	(2.5)	2.4	(4.9)
Worldwide	\$ 15,081	15,921	(5.3) %	(2.8)	(2.5)

	NINE MONTHS				
	2009	2008	Total	Percent Change	
				Operations	Currency
	\$ 5,125	5,282	(3.0) %	(3.0)	-
	6,429	6,917	(7.1)	4.1	(11.2)
	11,554	12,199	(5.3)	1.0	(6.3)
	9,703	11,401	(14.9)	(14.9)	-
	6,824	7,481	(8.8)	1.4	(10.2)
	16,527	18,882	(12.5)	(8.5)	(4.0)
	8,194	7,959	3.0	3.0	-
	9,071	9,525	(4.8)	3.7	(8.5)
	17,265	17,484	(1.3)	3.3	(4.6)
	23,022	24,642	(6.6)	(6.6)	-
	22,324	23,923	(6.7)	3.1	(9.8)
	\$ 45,346	48,565	(6.6) %	(1.8)	(4.8)

Johnson & Johnson and Subsidiaries**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

THIRD QUARTER

	2009	2008	Percent Change		
			Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 7,314	7,955	(8.1) %	(8.1)	-
Europe	3,879	4,076	(4.8)	2.1	(6.9)
Western Hemisphere excluding U.S.	1,338	1,461	(8.4)	1.5	(9.9)
Asia-Pacific, Africa	2,550	2,429	5.0	3.5	1.5
International	7,767	7,966	(2.5)	2.4	(4.9)
Worldwide	\$ 15,081	15,921	(5.3) %	(2.8)	(2.5)

NINE MONTHS

	2009	2008	Percent Change		
			Total	Operations	Currency
U.S.	\$ 23,022	24,642	(6.6) %	(6.6)	-
Europe	11,522	12,931	(10.9)	1.2	(12.1)
Western Hemisphere excluding U.S.	3,615	3,986	(9.3)	5.8	(15.1)
Asia-Pacific, Africa	7,187	7,006	2.6	5.1	(2.5)
International	22,324	23,923	(6.7)	3.1	(9.8)
Worldwide	\$ 45,346	48,565	(6.6) %	(1.8)	(4.8)

Johnson & Johnson and Subsidiaries**Condensed Consolidated Statement of Earnings**

(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER

	2009		2008		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 15,081	100.0	\$ 15,921	100.0	(5.3)
Cost of products sold	4,434	29.4	4,774	30.0	(7.1)
Selling, marketing and administrative expenses	4,767	31.6	5,195	32.6	(8.2)
Research expense	1,617	10.7	1,861	11.7	(13.1)
Interest (income)expense, net	114	0.7	25	0.2	
Other (income)expense, net	(96)	(0.6)	(224)	(1.4)	
Earnings before provision for taxes on income	4,245	28.2	4,290	26.9	(1.0)
Provision for taxes on income	900	6.0	980	6.1	(8.2)
Net earnings	\$ 3,345	22.2	\$ 3,310	20.8	1.1
Net earnings per share (Diluted)	\$ 1.20		\$ 1.17		2.6
Average shares outstanding (Diluted)	2,793.0		2,831.3		
Effective tax rate	21.2 %		22.8 %		

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

NINE MONTHS

	2009		2008		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 45,346	100.0	\$ 48,565	100.0	(6.6)
Cost of products sold	13,135	29.0	14,139	29.1	(7.1)
Selling, marketing and administrative expenses	14,172	31.3	15,825	32.6	(10.4)
Research expense	4,773	10.5	5,469	11.3	(12.7)
In-process research & development	-	-	40	0.1	
Interest (income)expense, net	280	0.6	57	0.1	
Other (income)expense, net	(165)	(0.4)	(377)	(0.8)	
Earnings before provision for taxes on income	13,151	29.0	13,412	27.6	(1.9)
Provision for taxes on income	3,091	6.8	3,177	6.5	(2.7)
Net earnings	\$ 10,060	22.2	\$ 10,235	21.1	(1.7)

Net earnings per share (Diluted) \$ 3.61 \$ 3.60 0.3

Average shares outstanding (Diluted) 2,787.9 2,847.8

Effective tax rate 23.5 % 23.7 %

Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$ 13,151	29.0	\$ 13,452 (1)	27.7	(2.2)
Net earnings	\$ 10,060	22.2	\$ 10,275 (1)	21.2	(2.1)
Net earnings per share (Diluted)	\$ 3.61		\$ 3.61 (1)		0.0
Effective tax rate	23.5%		23.6%		

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)										
<u>SKIN CARE</u>										
US	370	358	3.4%	3.4%	-	1,204	1,119	7.6%	7.6%	-
Intl	472	500	-5.6%	-0.1%	-5.5%	1,313	1,418	-7.4%	3.0%	-10.4%
WW	842	858	-1.9%	1.3%	-3.2%	2,517	2,537	-0.8%	5.0%	-5.8%
<u>BABY CARE</u>										
US	102	114	-10.5%	-10.5%	-	308	340	-9.4%	-9.4%	-
Intl	442	472	-6.4%	-0.7%	-5.7%	1,233	1,351	-8.7%	0.7%	-9.4%
WW	544	586	-7.2%	-2.6%	-4.6%	1,541	1,691	-8.9%	-1.4%	-7.5%
<u>ORAL CARE</u>										
US	187	204	-8.3%	-8.3%	-	549	588	-6.6%	-6.6%	-
Intl	223	230	-3.0%	4.8%	-7.8%	612	640	-4.4%	8.3%	-12.7%
WW	410	434	-5.5%	-1.4%	-4.1%	1,161	1,228	-5.5%	1.1%	-6.6%
<u>OTC/NUTRITIONALS</u>										
US	732	778	-5.9%	-5.9%	-	2,137	2,299	-7.0%	-7.0%	-
Intl	666	661	0.8%	8.0%	-7.2%	1,919	2,139	-10.3%	1.8%	-12.1%
WW	1,398	1,439	-2.8%	0.5%	-3.3%	4,056	4,438	-8.6%	-2.8%	-5.8%
<u>WOMEN'S HEALTH</u>										
US	142	164	-13.4%	-13.4%	-	443	470	-5.7%	-5.7%	-
Intl	360	346	4.0%	11.7%	-7.7%	963	1,005	-4.2%	7.2%	-11.4%
WW	502	510	-1.6%	3.6%	-5.2%	1,406	1,475	-4.7%	3.1%	-7.8%
<u>WOUND CARE / OTHER</u>										
US	158	151	4.6%	4.6%	-	484	466	3.9%	3.9%	-
Intl	135	121	11.6%	18.0%	-6.4%	389	364	6.9%	18.8%	-11.9%
WW	293	272	7.7%	10.5%	-2.8%	873	830	5.2%	10.5%	-5.3%
<u>TOTAL CONSUMER</u>										
US	1,691	1,769	-4.4%	-4.4%	-	5,125	5,282	-3.0%	-3.0%	-
Intl	2,298	2,330	-1.4%	5.2%	-6.6%	6,429	6,917	-7.1%	4.1%	-11.2%
WW	3,989	4,099	-2.7%	1.1%	-3.8%	11,554	12,199	-5.3%	1.0%	-6.3%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2)										
<u>ACIPHEX/PARIET</u>										
US	131	130	0.8%	0.8%	-	397	399	-0.5%	-0.5%	-
Intl	130	152	-14.5%	-9.0%	-5.5%	387	485	-20.2%	-9.3%	-10.9%
WW	261	282	-7.4%	-4.4%	-3.0%	784	884	-11.3%	-5.3%	-6.0%
<u>CONCERTA</u>										
US	205	190	7.9%	7.9%	-	707	622	13.7%	13.7%	-
Intl	79	208	-62.0%	-59.2%	-2.8%	238	345	-31.0%	-20.8%	-10.2%
WW	284	398	-28.6%	-27.2%	-1.4%	945	967	-2.3%	1.3%	-3.6%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>										
US	38	54	-29.6%	-29.6%	-	163	199	-18.1%	-18.1%	-
Intl	168	205	-18.0%	-15.2%	-2.8%	492	565	-12.9%	-4.3%	-8.6%
WW	206	259	-20.5%	-18.3%	-2.2%	655	764	-14.3%	-8.0%	-6.3%
<u>LEVAQUIN/FLOXIN</u>										
US	294	313	-6.1%	-6.1%	-	1,045	1,117	-6.4%	-6.4%	-
Intl	17	20	-15.0%	0.3%	-15.3%	53	63	-15.9%	1.4%	-17.3%
WW	311	333	-6.6%	-5.7%	-0.9%	1,098	1,180	-6.9%	-6.0%	-0.9%
<u>PROCRIT/EXPRESX</u>										
US	299	334	-10.5%	-10.5%	-	950	1,014	-6.3%	-6.3%	-
Intl	243	285	-14.7%	-9.6%	-5.1%	719	886	-18.8%	-9.0%	-9.8%
WW	542	619	-12.4%	-10.0%	-2.4%	1,669	1,900	-12.2%	-7.6%	-4.6%
<u>RAZADYNE/REMINYL</u>										
US	1	31	-96.8%	-96.8%	-	30	123	-75.6%	-75.6%	-
Intl	96	107	-10.3%	-3.8%	-6.5%	275	316	-13.0%	-1.2%	-11.8%
WW	97	138	-29.7%	-24.7%	-5.0%	305	439	-30.5%	-22.0%	-8.5%
<u>REMICADE</u>										
US	822	778	5.7%	5.7%	-	2,330	2,138	9.0%	9.0%	-
US Exports (4)	208	198	5.1%	5.1%	-	821	718	14.3%	14.3%	-
Intl	6	2	200.0%	198.7%	1.3%	15	6	150.0%	145.8%	4.2%
WW	1,036	978	5.9%	5.9%	-	3,166	2,862	10.6%	10.6%	-
<u>RISPERDAL/RISPERIDONE</u>										
US	35	122	-71.3%	-71.3%	-	223	1,196	-81.4%	-81.4%	-
Intl	157	198	-20.7%	-21.4%	0.7%	483	645	-25.1%	-21.3%	-3.8%
WW	192	320	-40.0%	-40.4%	0.4%	706	1,841	-61.7%	-60.4%	-1.3%
<u>RISPERDAL CONSTA</u>										
US	129	118	9.3%	9.3%	-	386	339	13.9%	13.9%	-
Intl	224	220	1.8%	10.2%	-8.4%	640	651	-1.7%	12.6%	-14.3%
WW	353	338	4.4%	9.9%	-5.5%	1,026	990	3.6%	13.0%	-9.4%
<u>TOPAMAX</u>										
US	72	606	-88.1%	-88.1%	-	642	1,674	-61.6%	-61.6%	-
Intl	103	122	-15.6%	-7.9%	-7.7%	317	377	-15.9%	-3.5%	-12.4%
WW	175	728	-76.0%	-74.7%	-1.3%	959	2,051	-53.2%	-50.9%	-2.3%
<u>VELCADE</u>										
US	-	1	-100.0%	-100.0%	-	-	4	-100.0%	-100.0%	-
Intl	231	189	22.2%	31.1%	-8.9%	652	575	13.4%	26.7%	-13.3%
WW	231	190	21.6%	30.5%	-8.9%	652	579	12.6%	25.8%	-13.2%
<u>OTHER</u>										
US	623	663	-6.0%	-6.0%	-	2,009	1,858	8.1%	8.1%	-
Intl	938	867	8.2%	13.6%	-5.4%	2,553	2,567	-0.5%	9.2%	-9.7%
WW	1,561	1,530	2.0%	5.1%	-3.1%	4,562	4,425	3.1%	8.8%	-5.7%
<u>TOTAL PHARMACEUTICAL</u>										
US	2,857	3,538	-19.2%	-19.2%	-	9,703	11,401	-14.9%	-14.9%	-
Intl	2,392	2,575	-7.1%	-1.9%	-5.2%	6,824	7,481	-8.8%	1.4%	-10.2%
WW	5,249	6,113	-14.1%	-11.9%	-2.2%	16,527	18,882	-12.5%	-8.5%	-4.0%
MAJOR NEW PHARM PRODUCTS (5)										
<u>PREZISTA</u>										
US	78	34	129.4%	129.4%	-	215	109	97.2%	97.2%	-
Intl	73	45	62.2%	77.0%	-14.8%	198	132	50.0%	70.0%	-20.0%
WW	151	79	91.1%	99.5%	-8.4%	413	241	71.4%	82.3%	-10.9%
<u>INVEGA</u>										
US	61	73	-16.4%	-16.4%	-	194	192	1.0%	1.0%	-
Intl	36	16	125.0%	142.5%	-17.5%	93	39	138.5%	168.1%	-29.6%
WW	97	89	9.0%	12.3%	-3.3%	287	231	24.2%	29.2%	-5.0%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
<u>MEDICAL DEVICES AND DIAG (2) (3)</u>										
<u>CORDIS (6)</u>										
US	233	259	-10.0%	-10.0%	-	731	929	-21.3%	-21.3%	-
Intl	407	431	-5.6%	-4.6%	-1.0%	1,251	1,375	-9.0%	-3.9%	-5.1%
WW	640	690	-7.2%	-6.6%	-0.6%	1,982	2,304	-14.0%	-10.9%	-3.1%
<u>DEPUY</u>										
US	740	698	6.0%	6.0%	-	2,268	2,129	6.5%	6.5%	-
Intl	544	533	2.1%	7.6%	-5.5%	1,631	1,717	-5.0%	6.8%	-11.8%
WW	1,284	1,231	4.3%	6.7%	-2.4%	3,899	3,846	1.4%	6.7%	-5.3%
<u>DIABETES CARE</u>										
US	332	349	-4.9%	-4.9%	-	908	990	-8.3%	-8.3%	-
Intl	302	318	-5.0%	-0.4%	-4.6%	877	966	-9.2%	0.2%	-9.4%
WW	634	667	-4.9%	-2.7%	-2.2%	1,785	1,956	-8.7%	-4.1%	-4.6%
<u>ETHICON</u>										
US	439	372	18.0%	18.0%	-	1,296	1,087	19.2%	19.2%	-
Intl	580	585	-0.9%	3.8%	-4.7%	1,717	1,835	-6.4%	3.6%	-10.0%
WW	1,019	957	6.5%	9.4%	-2.9%	3,013	2,922	3.1%	9.3%	-6.2%
<u>ETHICON ENDO-SURGERY</u>										
US	499	473	5.5%	5.5%	-	1,442	1,386	4.0%	4.0%	-
Intl	607	569	6.7%	10.9%	-4.2%	1,794	1,783	0.6%	10.6%	-10.0%
WW	1,106	1,042	6.1%	8.4%	-2.3%	3,236	3,169	2.1%	7.7%	-5.6%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>										
US	285	261	9.2%	9.2%	-	846	749	13.0%	13.0%	-
Intl	216	209	3.3%	7.0%	-3.7%	616	640	-3.8%	4.8%	-8.6%
WW	501	470	6.6%	8.2%	-1.6%	1,462	1,389	5.3%	9.3%	-4.0%
<u>VISION CARE</u>										
US	238	236	0.8%	0.8%	-	703	689	2.0%	2.0%	-
Intl	421	416	1.2%	-0.2%	1.4%	1,185	1,209	-2.0%	0.3%	-2.3%
WW	659	652	1.1%	0.2%	0.9%	1,888	1,898	-0.5%	0.9%	-1.4%
<u>TOTAL MEDICAL DEVICES AND DIAG</u>										
US	2,766	2,648	4.5%	4.5%	-	8,194	7,959	3.0%	3.0%	-
Intl	3,077	3,061	0.5%	3.8%	-3.3%	9,071	9,525	-4.8%	3.7%	-8.5%
WW	5,843	5,709	2.3%	4.1%	-1.8%	17,265	17,484	-1.3%	3.3%	-4.6%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) For external purposes, reported as U.S. sales

(5) Included in Other

(6) Includes sales of Drug-Eluting Stents for Q3 2009 of \$53, \$158 and \$211MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q3 2008 of \$97, \$192 and \$289MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for September YTD 2009 of \$189, \$507 and \$696MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for September YTD 2008 of \$433, \$650 and \$1,083MM Domestic, International and Worldwide respectively